Cambridge company recognized for potential Celiac-curing vaccine
ImmusanT Inc., the Cambridge company that is developing a vaccine that would allow people with Celiac disease to eat gluten, has received some important recognition.
Informa has named the company's drug one of the Top 10 Autoimmune/Anti-Inflammatory Projects to Watch. That has given new energy to ImmusanT executives as they enter Phase 2 of clinical trials.
One percent of the world's population has Celiac disease, an autoimmune disorder that triggers a defensive response to gluten.
"We believeā¦
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Jessica Bartlett Source Type: news
More News: Autoimmune Disease | Biotechnology | Celiac Disease | Clinical Trials | Coeliac Disease | Health | Health Management | Vaccines